Skip to main navigation Skip to search Skip to main content

Phase i dose-escalation study of MEDI-573, a bispecific, antiligand monoclonal antibody against IGFI and IGFII, in patients with advanced solid tumors

  • Paul Haluska
  • , Michael Menefee
  • , Elizabeth R. Plimack
  • , Jonathan Rosenberg
  • , Donald Northfelt
  • , Theresa LaVallee
  • , Li Shi
  • , Xiang Qing Yu
  • , Patricia Burke
  • , Jaiqi Huang
  • , Jaye Viner
  • , Jennifer McDevitt
  • , Patricia LoRusso

Research output: Contribution to journal › Article › peer-review

61 Scopus citations

Fingerprint

Dive into the research topics of 'Phase i dose-escalation study of MEDI-573, a bispecific, antiligand monoclonal antibody against IGFI and IGFII, in patients with advanced solid tumors'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science